These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21206484)

  • 21. Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region.
    Toth K; Kuppuswamy M; Doronin K; Doronina O; Lichtenstein D; Tollefson A; Wold W
    Virology; 2002 Sep; 301(1):99-108. PubMed ID: 12359450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice.
    Zsengeller ZK; Wert SE; Hull WM; Hu X; Yei S; Trapnell BC; Whitsett JA
    Hum Gene Ther; 1995 Apr; 6(4):457-67. PubMed ID: 7612702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors.
    Liu Q; Zaiss AK; Colarusso P; Patel K; Haljan G; Wickham TJ; Muruve DA
    Hum Gene Ther; 2003 May; 14(7):627-43. PubMed ID: 12804145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
    Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
    Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
    Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
    Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors.
    Camargo FD; Huey-Louie DA; Finn AV; Sassani AB; Cozen AE; Moriwaki H; Schneider DB; Agah R; Dichek DA
    Mol Ther; 2000 Nov; 2(5):496-504. PubMed ID: 11082323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticocaine catalytic antibodies.
    Deng SX; de Prada P; Landry DW
    J Immunol Methods; 2002 Nov; 269(1-2):299-310. PubMed ID: 12379369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.
    Matthews QL
    Mol Pharm; 2011 Feb; 8(1):3-11. PubMed ID: 21047139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.
    Cao H; Yang T; Li XF; Wu J; Duan C; Coates AL; Hu J
    Gene Ther; 2011 Feb; 18(2):173-81. PubMed ID: 20882053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA-CFTR in the respiratory tractus in patients with cystic fibrosis].
    Bellon G; Calmard L; Thouvenot D; Levrey H; Jagneaux V; Poitevin F; Malcus C; Accart N; Séné C; Layani MP; Aymard M; Bienvenu J; Courtney M; Döring G; Gilly B; Gilly R; Lamy D; Morel Y; Paulin C; Perraud F; Rodillon L; So S; Touraine F; Schatz C; Pavirani A
    C R Seances Soc Biol Fil; 1996; 190(1):109-42. PubMed ID: 8881273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver.
    Croyle MA; Chirmule N; Zhang Y; Wilson JM
    Hum Gene Ther; 2002 Oct; 13(15):1887-900. PubMed ID: 12396620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future potential for cocaine vaccines.
    Orson FM; Wang R; Brimijoin S; Kinsey BM; Singh RA; Ramakrishnan M; Wang HY; Kosten TR
    Expert Opin Biol Ther; 2014 Sep; 14(9):1271-83. PubMed ID: 24835496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.
    Wortmann A; Vöhringer S; Engler T; Corjon S; Schirmbeck R; Reimann J; Kochanek S; Kreppel F
    Mol Ther; 2008 Jan; 16(1):154-62. PubMed ID: 17848961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenoviruses as vectors for delivering vaccines to mucosal surfaces.
    Babiuk LA; Tikoo SK
    J Biotechnol; 2000 Sep; 83(1-2):105-13. PubMed ID: 11000466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.
    Gu L; Krendelchtchikova V; Krendelchtchikov A; Farrow AL; Derdeyn CA; Matthews QL
    Virology; 2016 Jan; 487():75-84. PubMed ID: 26499044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective repeat administration with adenovirus vectors to the muscle.
    Chen P; Kovesdi I; Bruder JT
    Gene Ther; 2000 Apr; 7(7):587-95. PubMed ID: 10819574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus vector-mediated gene transfer to regional lymph nodes.
    Labow D; Lee S; Ginsberg RJ; Crystal RG; Korst RJ
    Hum Gene Ther; 2000 Mar; 11(5):759-69. PubMed ID: 10757355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
    Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation.
    Setoguchi Y; Jaffe HA; Chu CS; Crystal RG
    Am J Respir Cell Mol Biol; 1994 Apr; 10(4):369-77. PubMed ID: 8136153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.